Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer

Steven A. Limentani, Adam M. Brufsky, John K. Erban, Mohammed Jahanzeb, Deborah Lewis

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Fingerprint Dive into the research topics of 'Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences